Table 2.
Details of antibiotic usage
| n (%) | Before PSM (n = 33) | After PSM (n = 21) |
|---|---|---|
| Purposes for using antibioticsa | ||
| Prophylaxis for pneumonia at BF | 14 (42.4) | 9 (42.9) |
| Pneumonia | 11 (33.3) | 9 (42.9) |
| Prophylaxis for sepsis at extracting teeth | 2 (6.1) | 1 (4.8) |
| Chronic bronchitis | 2 (6.1) | 0 (0.0) |
| Prophylaxis for PCP at the use of corticosteroids | 2 (6.1) | 1 (4.8) |
| Urinary tract infection | 1 (3.0) | 1 (4.8) |
| Fever | 1 (3.0) | 1 (4.8) |
| Cellulitis | 1 (3.0) | 0 (0.0) |
| Type of antibioticsa | ||
| AMPC/CVA | 21 (63.6) | 14 (66.7) |
| PIPC/TAZ | 5 (15.2) | 3 (14.3) |
| LVFX | 4 (12.1) | 3 (14.3) |
| ABPC/SBT | 3 (9.1) | 3 (14.3) |
| ST | 2 (6.1) | 1 (4.8) |
| CAM | 2 (6.1) | 0 (0.0) |
| AMPC | 1 (3.0) | 0 (0.0) |
| CEZ | 1 (3.0) | 0 (0.0) |
| MFLX | 1 (3.0) | 1 (4.8) |
| VCM | 1 (3.0) | 0 (0.0) |
| Anaerobic-spectrum agents | 26 (78.8) | 18 (85.7) |
| Duration of antibiotics use ≥ 1 week | 20 (60.6) | 12 (57.1) |
| Route of antibioticsa | ||
| Intravenous/oral | 9 (27.3)/28 (84.8) | 6 (28.6)/18 (85.7) |
AMPC, amoxicillin; AMPC/CVA, amoxicillin/clavulanate; BF, bronchofiberscopy; CAM, clarithromycin; CEZ, cefazolin; MFLX, moxifloxacin; PCP, Pneumocystis pneumonia; PIPC/TAZ, piperacillin/tazobactam; PSM, propensity score matching; ST, sulfamethoxazole-trimethoprim; VCM, vancomycin
aPatients were counted in more than one row